SONARSOURCE
6.12.2022 17:01:53 CET | Business Wire | Press release
SonarSource, the leading provider of Clean Code solution, today announced record growth in developer and enterprise customer adoption. With a 43% growth in its user base, SonarSource supports more than 400,000 organizations and seven million users. The Sonar solution leads the industry with total analyzed code – which now tops more than half a trillion lines of code for organizations across the world. By adding 5,000 paying customers in 11 months, Sonar now supports 21,000 enterprise customers including over 75% of Fortune 100 and nearly half of Fortune 500 companies. Much of this progress transpired on the heels of the Company closing a $412 million funding round, which brought its valuation to $4.7 billion. SonarSource’s massive momentum is driven by the recognition from enterprises everywhere that Clean Code is an organizational imperative for long-term competitiveness and market success.
A Rapid Pace of Innovation
With a laser focus on empowering developers to deliver Clean Code, Sonar continues its tradition of innovation. Following a steady cadence of releases that add value to their community and enterprise users, Sonar continued to expand its analysis capabilities to be the most comprehensive, precise, and fastest in the market. Sonar solution, with 5,000 rules, now supports over 30 languages, frameworks, and infrastructure technologies including Infrastructure-as-Code support for secure Cloud Native applications and containerized development with Kubernetes rules. Improvements include the detection of complex bugs and faster analysis for the majority of the flagship languages, as well as stronger Kotlin and Java analysis for secure Android Mobile app development. Sonar’s enterprise capabilities got a big boost with enhanced compliance functionality, reporting, and better admin controls. Sonar continues to increase value to the developers as they write code in their preferred IDE with new capabilities and a frictionless experience when finding and fixing issues at every stage in their existing development workflow.
Global Team Expansion to Accelerate Momentum
To support this rapid acceleration, SonarSource has expanded its global staff to more than 400, opened a new APAC office in Singapore and expanded its presence in Austin, Texas, and LATAM. The Company also added to its leadership team, by naming a new CMO Manish Gupta, and a new General Counsel, Derek Smith this year.
“We are on a mission to help organizations deliver Clean Code, code that is secure, robust, and can evolve. This is the single step needed to make software an asset instead of a liability,” said Olivier Gaudin, Founder and CEO of SonarSource. “Our journey has been incredible, and we’re delighted with the accelerated user and customer adoption of our Sonar solution. SonarSource’s success is deeply rooted in the steadfast support from the developer community.”
About SonarSource
SonarSource’s Clean Code solution enables developers and development teams to write clean code and remediate existing code organically, so they can focus on the work they love and maximize the value they generate for businesses. Its open source and commercial Sonar solution – SonarLint, SonarCloud, and SonarQube – support over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar has become integral to delivering software.
To learn more about SonarSource, please visit https://www.sonarsource.com/company/about/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
